Information de reference pour ce titreAccession Number: | 00000406-200201000-00011.
|
Author: | Cohen, Marc MD a; Antman, Elliott M. MD b; Murphy, Sabina A. MPH c; Radley, David MS d
|
Institution: | Philadelphia, Pa, Boston, Mass, and Bridgewater, NJ From the (a) Division of Cardiology, MCP-Hahnemann University School of Medicine, Philadelphia, Pennsylvania.(b)Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.(c)Harvard Clinical Research Institute, and (d) previously with Aventis Pharma, Bridgewater, New Jersey.
|
Title: | |
Source: | American Heart Journal. 143(1):63-69, January 2002.
|
Abstract: | Background: Clarification of the specific clinical course of non-ST-segment elevation acute coronary syndromes (NSTEMI ACS), including recurrent ischemic events and need for coronary revascularization, is important given the increasing economic pressure to shorten the length of hospitalization and therefore the duration of acute therapy. To examine the mode and timing of subsequent cardiac events, we analyzed pooled data from the ESSENCE and TIMI 11B studies of antithrombotic therapy in NSTEMI ACS.
Methods: The daily event rates (with confidence intervals) during the first 43 days and the monthly average event rates during the first year were tabulated for 7081 patients.
Results: The median antithrombotic treatment duration was 3.2 days, whereas the highest absolute frequency of recurrent angina prompting urgent revascularization, myocardial infarction, or death after hospital admission occurred on day 2, day 3, and day 8, respectively. Coronary revascularization was performed in 32% of patients, with the greatest number occurring on day 4. Only 12% of the end point events were adjudicated as being periprocedural. The median length of hospital stay was 7 days.
Conclusions: Despite aggressive antithrombotic therapy, a significant proportion of patients with NSTEMI ACS have recurrent ischemia precipitating urgent revascularization or infarction within the first few days, whereas the highest risk of death occurs later, after the first week. (Am Heart J 2002;143:63-9.)
(C) 2002Elsevier, Inc.
|
References: | 1. Furman MI, Dauerman HL, Goldberg RJ, Yarzbeski J, Lessard D, Gore JM. Twenty-two year (1975-1997) trends in the incidence, in-hospital and long term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective. J Am Coll Cardiol 2001;37:1571-80.
2. Armstrong PW, Fu Y, Chang W-C, et al. Acute coronary syndromes in the GUSTO-IIB trial: prognostic insights and impact of recurrent ischemia. Circulation 1998;98:1860-8.
3. Greenbaum AB, Hudson MP, MacAulay CM, et al. Timing of events after hospitalization for acute coronary syndrome. Circulation 1998;98(Suppl-I):I-630.
4. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med 1997;337:447-52.
5. Antman EM, McCabe CH, Gurfinkel EP, et al for the TIMI 11B investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-601.
6. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-8.
7. Tavazzi L. Clinical epidemiology of acute myocardial infarction. Am Heart J 1999;138:48-54.
8. Fulton M, Lutz W, Donald KW, et al. Natural history of unstable angina. Lancet 1972;1:860-5.
9. Gazes PC, Mobley EM Jr, Faris HM Jr, Duncan RC, Humphries GB. Preinfarction (unstable) angina: a prospective study: ten-year follow-up. Prognostic significance of electrocardiographic changes. Circulation 1973;48:331-7.
10. Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosis and management. Clinical Practice Guideline Number 10. AHCPR Publication No. 94-0602. Rockville, MD: Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, U.S. Department of Health and Human Services. March 1994. Page 15, Figure 1; Unpublished data, Duke Cardiovascular databank.
11. Cohen M, Xiong J, Parry G, et al. Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. J Am Coll Cardiol 1993;22:1338-43.
12. van Domburg RT, van Miltenburg-van Zijl AJ, Veerhoek RJ, Simoons ML. Unstable angina: good long-term outcome after a complicated early course. J Am Coll Cardiol 1998;31:1534-9.
13. Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998;338:1785-92.
14. Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: a randomised trial. Lancet 1999;353:429-38.
15. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
16. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
17. FRragmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC II) Investigators. Long-term low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354:701-7.
18. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: executive summary and recommendations: Circulation 2000;102:1193-209.
19. Bahit MC, Topol EJ, Califf RM, et al. Reactivation of ischemic events in acute coronary syndromes: results from Gusto-IIb. J Am Coll Cardiol 2001;37:1001-7.
20. FRagmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC II) Investigators. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354:708-15.
21. Cannon CP, Weintraub WS, Demopoulos LA, Robertson DH, Gormley GJ, Braunwald E for the TACTICS-TIMI 18 investigators. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction. Am J Cardiol 1998;82:731-6.
22. Jacobs DR Jr, Kroenke C, Crow R, et al. PREDICT: A simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: the Minnesota heart survey. Circulation 1999;100:599-607.
23. Cohen M, Stinnett SS, Weatherley BD, et al. Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. Am Heart J 2000;139:962-70.
24. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for Unstable Angina/Non ST elevation MI. A method for prognostication and therapeutic decision making. JAMA 2000;284:835-42.
25. Boersma E, Pieper KS, Steyerberg EW, et al for the PURSUIT Investigators. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: Results from an international trial of 9461 patients. Circulation 2000;101:2557-67.
26. Lotan CS, Jonas M, Rozenman Y, et al. Comparison of early invasive and conservative treatments in patients with anterior wall non-Q-wave acute myocardial infarction. Am J Cardiol 1995;76:330-6.
27. Kleiman NS, Lincoff AM, Flaker GC, et al for the PURSUIT Investigators. Early percutaneous coronary interventions, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. Circulation 2000;101:751-7.
28. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
|
Language: | English.
|
Document Type: | Clinical Investigations: Acute Ischemic Heart Disease.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0002-8703
|
NLM Journal Code: | 3bw, 0370465
|
Annotation(s) | |
|
|